文献速递血栓与止血浆细胞疾病

直接口服抗凝药对比阿司匹林用于接受门诊治疗的多发性骨髓瘤患者一级血栓预防:系统综述与更新荟萃分析

Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysis.
PubMed 文献 · Br J Haematol · 2023-08-02

该系统综述与荟萃分析纳入10项随机对照试验和观察性研究、共1026例接受门诊抗骨髓瘤治疗的多发性骨髓瘤患者,比较直接口服抗凝药(DOAC)与阿司匹林用于一级血栓预防。DOAC组静脉血栓栓塞发生率显著低于阿司匹林组(OR 0.33;95%CI 0.16-0.68;p<0.001),大出血、临床相关非大出血及小出血事件率两组无显著差异。作者认为DOAC可能优于阿司匹林,但需考虑基线人群异质性和观察性研究偏倚,尚需进一步研究。

要点

  • DOAC组静脉血栓栓塞发生率显著低于阿司匹林组(OR 0.33;95%CI 0.16-0.68;p<0.001)。
  • 大出血、临床相关非大出血及小出血事件率两组无显著差异。
  • 作者认为DOAC可能优于阿司匹林,但需考虑基线人群异质性和观察性研究偏倚。

核心结论

  • 作者认为DOAC可能优于阿司匹林用于预防多发性骨髓瘤相关血栓形成。
  • 作者指出结果需在基线人群特征异质性和纳入观察性研究潜在偏倚的背景下解读。
  • 作者提出需进一步研究评估最佳血栓预防策略,尤其在高危个体中。

研究设计与样本

  • 系统综述与更新荟萃分析,纳入10项随机对照试验和观察性研究。
  • 共1026例接受门诊抗骨髓瘤治疗并接受一级血栓预防的多发性骨髓瘤患者。
  • DOAC组337例,阿司匹林组689例。

主要发现

  • DOAC组静脉血栓栓塞发生率显著低于阿司匹林组(OR 0.33;95%CI 0.16-0.68;p<0.001)。
  • 大出血、临床相关非大出血及小出血事件率两组无显著差异。

关键数值与推荐

  • 纳入标准为比较DOAC与阿司匹林的血栓和出血结局的研究。
  • DOAC组静脉血栓栓塞OR 0.33(95%CI 0.16-0.68;p<0.001),与阿司匹林组比较。

临床怎么用

  • 当前指南建议低剂量DOAC作为阿司匹林的替代方案用于该人群一级血栓预防,但比较两种疗法的数据有限。
  • 作者认为DOAC可能优于阿司匹林用于预防多发性骨髓瘤相关血栓形成。
  • 作者提出需进一步研究评估最佳血栓预防策略,尤其在高危个体中。

局限性

  • 基线人群特征存在异质性。
  • 纳入观察性研究可能带来偏倚。
  • 需进一步研究评估最佳血栓预防策略,尤其在高危个体中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with multiple myeloma (MM) are at an elevated risk of venous thromboembolism (VTE), which is further increased for those undergoing anti-myeloma therapy. Current guidelines suggest low-dose direct oral anticoagulants (DOACs) as an alternative to aspirin for primary thromboprophylaxis in this population, but data comparing these two therapies are limited. We performed a systematic review and meta-analysis to compare DOACs with aspirin for primary thromboprophylaxis in individuals undergoing outpatient anti-myeloma therapy. Studies were selected when comparing DOACs versus aspirin for thrombotic and haemorrhagic outcomes. We included 10 randomised controlled trials and observational studies comprising 1026 patients with MM who received primary thromboprophylaxis with DOACs (n = 337) or aspirin (n = 689). DOAC thromboprophylaxis was associated with a significantly lower incidence of VTE compared with aspirin (OR 0.33; 95% CI 0.16-0.68; p < 0.001). Major, clinically relevant non-major and minor bleeding event rates did not differ significantly between groups. Overall, our meta-analysis suggests that DOACs may be a preferable option to aspirin for the prevention of MM-related thrombosis. However, these results should be interpreted in the context of heterogeneous baseline population characteristics and potential bias from including observational studies. Further research is needed to evaluate the optimal thromboprophylaxis strategy, particularly in high-risk individuals.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Costa TA, Felix N, Costa BA, et al. Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysis. Br J Haematol. 2023. PMID: 37533165. doi:10.1111/bjh.19017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。